Progesterone receptor expression and proliferative activity in relation to histological architecture of feline mammary fibroadenomatous change

• Autorzy: Krawczyk M. , Lopuszynski W. , Szczubial M. , Millan Y.
• Języki publikacji: EN

Abstrakty

EN

The aim of the study was to determine the relationship between histological architecture and progesterone receptor expression as well as proliferative activity in feline mammary fibroadenomatous change (FMFAC) in female cats. The investigations were performed on 16 surgically removed FMFAC diagnosed based on their gross and microscopic appearance. The lesions were divided into 2 groups based on the number of epithelium layers: lesions with two or less ductal epithelium layers formed group A and lesions with more than two layers of epithelial cells were assigned to group B. Moreover, in each group the lesions were classified according to the cellularity of stroma into three subgroups (with poor, moderate and abundant cellularity). Immunohistochemical examinations were carried out to detect an expression of progesterone receptors (PRs) and a proliferative activity (based on Ki-67 antigen expression). The PR expression and Ki-67 antigen expression were significantly higher in epithelial cells than in stromal cells; however, the differences in above mentioned markers in ductal epithelium and stromal cells between studied groups were not significant. The results of this study indicate that there is no relationship between histological appearance, PR expression and proliferative activity in FMFAC. Moreover, a high percentage of PR-expressing cells in duct epithelium may explain the regression of enlarged mammary gland after administration of progesterone receptor blockers.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2017
• Tom: 73
• Numer: 01
• Opis fizyczny: p.33-38,fig.,ref.

Twórcy

autor

Krawczyk M.

• Department of Animal Reproduction, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Gleboka 30, 20-033 Lublin, Poland

autor

Lopuszynski W.

• Department of Pathological Anatomy, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Gleboka 30, 20-033 Lublin, Poland

autor

Szczubial M.

• Department of Animal Reproduction, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Gleboka 30, 20-033 Lublin, Poland

autor

Millan Y.

• Department of Anatomy and Comparative Pathology, Faculty of Veterinary Medicine, University of Córdoba, Campus Universitario de Rabanales, Carretera Madrid - Cadiz Km, 396. 14071 Cordoba, Spain

Bibliografia

• Allen H. L.: Feline mammary hypertrophy. Vet. Pathol. 1973, 10, 501-508.
• Burstyn U.: Management of mastitis and abscessation of mammary glands secondary to fibroadenomatous hyperplasia in a primiparturient cat. J. Am. Vet. Med. Assoc. 2010, 236, 326-329.
• Cadepond F., Ulmann A., Baulieu E. E.: RU 486 (mifepristone): mechanisms of action and clinical uses. Annu. Rev. Med. 1997, 48, 129-159.
• Connelly O. M., Mulac-Jericevic B., Lydon J. P.: Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 2003, 68, 771-778.
• Dias Pereira P., Carvalheira J., Gärtner F.: Cell proliferation in feline normal, hyperplastic and neoplastic mammary tissue – an immunohistochemical study. Vet. J. 2004, 168, 180-185.
• Donnay I., Rauïs J., Devleeschouwer N., Wouters-Ballman P., Leclercq G., Verstegen J.: Comparison of estrogen and progesterone receptor expression in normal and tumor mammary tissues from dogs. Am. J. Vet. Res. 1995, 56, 1188-1194.
• Goldschmidt M., Peña L., Rasotto R., Zappulli V.: Classification and grading of canine mammary tumors. Vet. Pathol. 2011, 48, 117-131.
• Goodson W. H., Moore D. H., Ljung B. M., Chew K., Mayall B., Smith H. S., Waldman F. M.: The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Research and Treatment. 2000, 59, 113-123.
• Görlinger S., Kooistra H. S., Broek A. van den, Okkens A. C.: Treatment of fibroadenomatous hyperplasia in cats with aglepristone. J. Vet. Intern. Med. 2002, 16, 710-713.
• Guil-Luna S., Sanchez-Cespedes R., Millan Y., De Andres F. J., Rollon E., Domingo V., Guscetti F., Martin de las Mulas J.: Algepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas. J. Vet. Inter. Med. 2011, 25, 518-523.
• Guray M., Sahin A. A.: Benign breast diseases: classification, diagnosis, and management. Oncologist. 2006, 11, 435-449.
• Hayden D. W., Barnes D. M., Johnson K. H.: Morphologic changes in the mammary gland of megestrol acetate-treated and untreated cats: a retrospective study. Vet. Pathol. 1989, 26, 104-113.
• Hayden D. W., Johnson K. H., Ghobrial H. K.: Ultrastructure of feline mammary hypertrophy. Vet. Pathol. 1983, 20, 254-264.
• Hayden D. W., Johnston S. D., Kiang D. T., Johnson K. H., Barnes D. M.: Feline mammary hyperthrophy/fidroadenoma complex: clinical and hormonal aspects. Am. J. Vet. Res. 1981, 42, 1699-1703.
• Hinton M., Gaskell C. J.: Non-neoplastic mammary hypertrophy in the cat associated either with pregnancy or with oral progestagen therapy. Vet. Rec. 1977, 100, 277-280.
• Hughes K., Dobson J. M.: Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet. J. 2012, 194, 19-26.
• Jelinek F., Barton R., Posekana J., Hasonova L.: Gynaecomastia in a tom-cat caused by cyproterone acetate: a case raport. Vet. Med. 2007, 52, 521-525.
• Jurka P., Max A.: Treatment of fibroadenomatosis in 14 cats with aglepristone – changes in blood parameters and follow-up. Vet. Rec. 2009, 165, 657-660.
• Krimer P. M., Harvey S. B., Blas-Machado U., Lauderdale J. D., Moore P. A.: Reversible fibroadenomatous mammary hyperplasia in male and female New Zealand white rabbits associated with cyclosporine A administration. Vet. Pathol. 2009, 46, 1144-1148.
• Loretti A. P., Ilha M. R. S., Breitsameter I., Faraco C. S.: Clinical and pathological study of feline mammary fibroadenomatous change associated with depot medroxyprogesterone acetate therapy. Arq. Bras. Med. Vet. Zootec. 2004, 56, 270-274.
• MacDougall L. D.: Mammary fibroadenomatous hyperplasia in a young cat attributed to treatment with megestrol acetate. Can. Vet. J. 2003, 44, 227-229.
• Millanta F., Calandrella M., Vannozzi I., Poli A.: Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet. Rec. 2006, 158, 821-824.
• Millanta F., Lazzeri G., Mazzei M., Vannozzi I., Poli A.: MIB-1 labelling index in feline dysplastic and neoplastic mammary lesions and its relationship with postsurgical prognosis. Vet. Pathol. 2002, 39, 120-126.
• Misdorp E., Else R. W., Hellmén E., Lipscomb T. P.: Histological classification of mammary tumours of the dog and cat. Second series. WHO international histological classification of tumors of domestic animals. Washington DC, Armed Forces Institute of Pathology. Vol. VII, 1999.
• Mol J. A., Garderen E. van, Rutteman G. R., Rijnberk A.: New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary gland of dogs, cats and humans. J. Steroid Biochem. Molec. Biol. 1996, 57, 67-71.
• Mol J. A., Gracanin A., Gier J. de, Rao N., Schaefers-Okkens A., Rutteman G. R., Kooistra H.: Molecular genetics and biology of progesterone signaling in mammary neoplasia. Proc. of the joint meeting of the 7th International Symposium on Canine and Feline Reproduction and the 15th Congress of the European Veterinary Society for Small Animal Reproduction. British Columbia 2012, p. 107-108.
• Mulas J. M. de las, Millán Y., Bautista M. J., Pérez J., Carrasco L.: Ostrogen and progesterone receptors in feline fibroadenomatous change: an immunohistochemical study. Res. Vet. Sci. 2000, 68, 15-21.
• Ordás J., Millán Y., Monteros A. E. de los, Reymundo C., Mulas J. M. de las: Immunohistochemical expression of progesterone receptors, growth hormone and insulin growth factor-I in feline fibroadenomatous change. Res. Vet. Sci. 2004, 76, 227-233.
• Ozenc E., Bozkurt M. F.: Atypical fibroepithelial hyperplasia of the teats in a Sphynx cat: a case report. Vet. Med. 2014, 59, 265-269.
• Peña L. L., Nieto A. I., Pérez-Alenza M. D., Cuesta P., Castaño M.: Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J. Vet. Diagn. Invest. 1998, 10, 237-246.
• Remmele W., Stegner H. E.: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8, 138-140.
• Rutteman G. R., Misdorp W.: Hormonal background of canine and feline mammary tumours. J. Reprod. Fertil. 1993, 47 (Supp.), 483-487.
• Seixas F., Palmeira C., Pires M. A., Bento M. J., Lopes C.: Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis. Vet. J. 2011, 187, 65-71.
• Szczubiał M., Łopuszyński W.: Włókniakogruczolak gruczołu mlekowego u jednorocznej kotki. Magazyn Wet. 1997, 6, 358-359.
• Wehrend A., Hospes R., Gruber A. D.: Treatment of feline mammary fibroadenomatous hyperplasia with a progesterone-antagonist. Vet. Rec. 2001, 148, 346-347.

Identyfikatory

DOI

10.21521/mw.5626